Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on AEZS, AMPE, ELN and MDCO Issued by the Bedford Report

T.AEZS, AMPE
Free Research Reports on AEZS, AMPE, ELN and MDCO Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=995534&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 03/12/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

AEterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) shares declined 22.52 percent on volume of over 4.3 million shares traded Monday to close at $2.03 a share. The company announced it has been recommended to discontinue its Phase 3 trial of its multiple myeloma treatment.

Find out more about AEterna Zentaris including full access to the free equity report at: www.BedfordReport.com/AEZS

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) shares spiked 8.52 percent on more than double the average daily volume Monday to close at $4.33 a share. The company announced that the FDA has accepted its POPE questionnaire, paving the way for its U.S. pivotal trial on Zertane.

Find out more about Ampio Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/AMPE

Elan Corporation, plc (NYSE: ELN) shares gained 3.66 percent on volume over 7.18 million shares traded Monday to close at $11.88 a share. The company recently announced they will offer as much as $13 a share, roughly a 13 premium to Friday's closing price, in a $1 billion stock buyback plan.

Find out more about Elan including full access to the free equity report at: www.BedfordReport.com/ELN

The Medicines Company (NASDAQ: MDCO) traded in the range of $32.10 to $33.71 Monday before closing at $32.24 a share on volume of 1.68 million shares traded. The company recently announced its intravenous cangrelor demonstrated a 22 percent reduction in ischemic events.

Find out more about The Medicines Company including full access to the free equity report at: www.BedfordReport.com/MDCO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact